Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Kevin L WinthropPeter NashKunihiro YamaokaEduardo MyslerNasser KhanHeidi S CampYanna SongJessica L SubotickiJeffrey R CurtisPublished in: Annals of the rheumatic diseases (2021)
In the UPA phase III RA clinical programme, HZ incidence and event rates were higher with UPA versus ADA + MTX or MTX monotherapy, and higher with the 30 mg versus 15 mg dose. Patients from Asia and those with a history of HZ may be at increased risk of HZ while receiving UPA.
Keyphrases
- phase iii
- clinical trial
- open label
- phase ii
- double blind
- end stage renal disease
- placebo controlled
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- prognostic factors
- peritoneal dialysis
- chronic kidney disease
- risk factors
- randomized controlled trial
- combination therapy
- patient reported outcomes
- ankylosing spondylitis